welcome to cyprotex
home > investor relations > corporate governance

Corporate Governance

The Board recognises that good Corporate Governance and compliance with the Hampel Combined Code are fundamental to the successful management of the Company. Cyprotex PLC has established the appropriate procedures to deliver compliance in line with the size of the Group. The Board, including the Non-Executive Directors, understand that their responsibilities opposite the ongoing annual review of internal controls encompass the pro-active management of risk in terms of strategy, finance and operations and are on track to ensure that a full suite of necessary procedures are in place.

The Board meets regularly throughout the year and Directors are provided with papers ahead of the meeting which review strategic, financial and operational performance and point up key issues for the business going forward. An annual budgeting process is in place. The Board has established an Audit Committee and a Remuneration Committee with formally delegated duties and responsibilities. Each Committee comprises a Non-Executive Director as Chairman at least one other Director and, in the case of the Audit Committee, an Executive Director.

The Audit Committee determined the terms of engagement of the group's auditors and will determine in consultation with the auditors, the scope of the audit, having scoped the interim accounts report and signed it off before Board approval. It will receive and review reports from management and the Groups auditor's relating to the Annual Accounts and future Interims and the accounting and internal control systems in use throughout the Group. The Audit Committee has unrestricted access to the Group's Auditors.

The Remuneration Committee reviews the scale and structure of the Executive Directors remuneration and the terms of their Service Contracts, including share option schemes. The remuneration and the terms and conditions of appointment of the Non-Executive Directors will be set by the Board as a whole.

The Company places a high priority on its relations with institutional and private shareholders. It will ensure that as well as holding relevant regular and timely meetings with institutional and major shareholders it designs AGM meetings which inform and clearly explain Company performance.

Click here to access the Admission Document to the Alternative Investment Market of Cyprotex PLC

Click here to access the Articles of Association of Cyprotex PLC adopted by Special Resolution on 14th July 2009

contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 8th September 2010
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.